Stratec (SBS) Investor presentation summary

Business overview and market position

• Leading OEM provider of automation solutions for diagnostics and translational research, with over 1,400 employees and production sites in Europe and the US.

• Installed base of around 50,000 systems globally, with a 2025 sales figure of €250.9 million.

• Focuses on high-complexity, fast-growing IVD market segments such as molecular diagnostics, immunoassay, and immunohematology.

• Benefits from the ongoing trend of outsourcing instrumentation development by diagnostics companies.

• Maintains long-term customer relationships with global top 20 IVD companies and technology pioneers.

Revenue streams and financial performance

• Recurring revenue from service parts and consumables represents 41% of sales, with systems at 35% and development/services at 24%.

• HI 2026 sales declined 3.3% yoy at constant currency to €112.5 million, mainly due to temporary logistics optimization at customers.

• Adjusted EBIT margin for HI 2026 was 6.9%, nearly matching the prior year, despite a decrease in high-margin consumables.

• Strong free cash flow in HI 2026 (€23.5 million), driven by reduced trade receivables.

• Net debt reduced by 14% to €96.7 million, with an equity ratio of 58.1%.

Strategic outlook and growth targets

• 2026 sales expected to grow in the mid-to-high single-digit percentage range, with adjusted EBIT margin at prior year’s level (10%).

• Focus on cost discipline, efficient transfer of new systems to production, and mitigating profitability dilution from certain business units.

• Sales CAGR targeted at 6–8% (2025–2028) and 10–12% (2028–2030), with adjusted EBIT margin goals of at least 13% by 2028 and 15% by 2030.

• Pipeline includes next-generation immunoassay, molecular, and immunohematology systems, with strong emphasis on automation and decentralized testing.

• Plans to rebuild profitability through commercial and operational excellence, pricing, and portfolio optimization.